SCHEMBL13642319

SCHEMBL13642319

C[C@H](CCC(O)C(C)(C)O)[C@H]1CC[C@@]2(C)C3CCC4C(C)(C)[C@@H](C)CC[C@@]45C[C@@]35CC[C@]12C

nearest known ligand 0.62

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ HSD11B1 P28845 4/20 0.62
▸ HSD11B2 P80365 1/20 0.62
▸ ACLY P53396 2/20 0.50
▸ ACACA Q13085 2/20 0.50
▸ PTPN11 Q06124 1/20 0.47
▸ PRKAG1 P54619 1/20 0.43
▸ PRKAA2 P54646 1/20 0.43
▸ PRKAB1 Q9Y478 1/20 0.43
▸ ACHE P22303 2/20 0.42
▸ TOP2A P11388 6/20 0.42
▸ TOP2B Q02880 6/20 0.42
▸ FNTA P49354 1/20 0.39
▸ FNTB P49356 1/20 0.39
▸ PTGS1 P23219 1/20 0.37
▸ PTGS2 P35354 1/20 0.37
▸ ESR2 Q92731 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13642588 1.00 HSD11B1 (0.62) HSD11B1HSD11B2ACLYACACAPTPN11
3Beta,24,25-Trihydroxycycloartane SCHEMBL3306653 0.90 HSD11B1 (0.76) HSD11B1HSD11B2ACLYACACAPTPN11
SCHEMBL13642569 0.86 ACLY (0.52) HSD11B1HSD11B2ACLYACACAPTPN11
SCHEMBL13642701 0.85 ACLY (0.56) HSD11B1HSD11B2ACLYACACAPTPN11
SCHEMBL13642589 0.85 ACLY (0.56) HSD11B1HSD11B2ACLYACACAPTPN11
SCHEMBL13420506 0.84 HSD11B1 (0.63) HSD11B1HSD11B2ACLYACACAPTPN11
SCHEMBL14046872 0.84 HSD11B1 (0.63) HSD11B1HSD11B2ACLYACACAPTPN11
SCHEMBL13420348 0.84 HSD11B1 (0.63) HSD11B1HSD11B2ACLYACACAPTPN11
SCHEMBL13642529 0.83 ACLY (0.54) HSD11B1HSD11B2ACLYACACAPTPN11
SCHEMBL13642672 0.82 ACLY (0.53) HSD11B1HSD11B2ACLYACACAPTPN11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120283217-A1 MODULATORS OF AMYLOID-BETA PRODUCTION SATORI PHARMACEUTICALS, INC. (US) 2012-11-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120283217-A1 MODULATORS OF AMYLOID-BETA PRODUCTION APP, BACE1, BACE2 HSD11B1 661/4885HSD11B2 767/4885ACLY 668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback